Michigan is currently home to 2249 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence
Recruiting
The masseter muscle is one of the muscles in the lower face used for chewing. The prominence of the masseter muscle can appear as a widened lower face which some individuals deem as aesthetically undesirable and can be treated by selectively weakening the masseter muscles with small quantities of botulinum toxin. The purpose of this study is to assess how safe and effective injection of onabotulinumtoxinA (BOTOX) is in adult participants with Masseter Muscle Prominence (MMP). BOTOX is being inv... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Clarkston Dermatology /ID# 248888, Clarkston, Michigan
Conditions: Masseter Muscle Prominence
Evaluation of Quality-of-Life Improvements Using UroShield Device
Recruiting
The goal of this pilot study is to test key elements of the full study that will follow, including recruitment and retention strategies, intervention delivery, laboratory testing, data collection methods, and adherence to study protocol. The main questions the investigators aim to answer focus on implementation and practicality: Recruitment feasibility and time to recruit How well do participants adhere to device protocol? How often do device components (i.e., actuators and drivers) have to be... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Evangelical Home - Saline, Saline, Michigan
Conditions: Quality of Life, Catheter-Associated Urinary Tract Infection
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
Recruiting
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). The purpose of this study is to assess how safe and effective lutikizumab is in adult subjects with UC and how lutikizumab compares to adalimumab in the treatment of UC. Adverse events and changes in disease activity will be assessed. Lutikizumab is an investigational product being developed for the treatment of UC. Participants are pla... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Clin Res Inst of Michigan, LLC /ID# 258386, Chesterfield, Michigan
Conditions: Ulcerative Colitis
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
Recruiting
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Oakland Hills Dermatology Pc, Auburn Hills, Michigan
Conditions: Atopic Dermatitis
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
Recruiting
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with LY3841136 compared with placebo in adult participants with obesity or overweight. The study will last about 64 weeks and may include up to 13 visits.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/20/2024
Locations: Headlands Research - Detroit, Southfield, Michigan
Conditions: Obesity, Overweight and Obesity
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
Recruiting
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 [NCT05620823] or INCB 54707-302 [NCT05620836]).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Investigative Site US213, Fort Gratiot, Michigan
Conditions: Hidradenitis Suppurativa (HS)
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
Recruiting
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Great Lakes Research Group Inc, Bay City, Michigan
Conditions: NonSegmental Vitiligo
Post-Market Registry of the Patient Experience When Using UltraGuideCTR for Carpal Tunnel Release
Recruiting
Multicenter prospective registry of patients with symptomatic Carpal Tunnel Syndrome treated with Ultrasound Guided Carpal Tunnel Release (CTR-US).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Mendelson Orthopedic PC, Troy, Michigan
Conditions: Carpal Tunnel Syndrome, CTS
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Recruiting
Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children, but most cases occur in adults. This study is to evaluate how safe ABBV-787 is and how it moves within the body in adult participants with relapsed/refractory (R/R) acute myeloid leukemia (AML). Adverse events and maximum tolerated dose (MTD) of ABBV-787 will be assessed. ABBV-787 is an investigational drug being developed for the treatment of AML. Participants will receive ABBV-787 in esca... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Cancer & Hematology Centers /ID# 252803, Grand Rapids, Michigan
Conditions: Acute Myeloid Leukemia
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
Recruiting
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many different symptoms including abdominal pain, diarrhea, tiredness, and weight loss. This study will assess how safe and effective risankizumab subcutaneous (SC) induction treatment is in treating moderately to severely active CD in adult participants. Risankizumab is an approved drug for adults with CD. This study comprises... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Clin Res Inst of Michigan, LLC /ID# 256609, Chesterfield, Michigan
Conditions: Crohn's Disease
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
Recruiting
The primary objective of the study is to demonstrate the efficacy of high dose and low dose fluticasone propionate (Fp)/albuterol sulfate (ABS) integrated electronic module multidose dry powder inhaler (eMDPI) compared to ABS eMDPI in decreasing severe clinical asthma exacerbation (CAEs). Secondary Objectives: To evaluate the efficacy of Fp/ABS compared to ABS and the effect on systemic corticosteroid (SCS) exposure To evaluate the safety and tolerability of Fp/A BS The duration for each part... Read More
Gender:
All
Ages:
4 years and above
Trial Updated:
05/20/2024
Locations: Teva Investigational Site 15593, Ypsilanti, Michigan
Conditions: Asthma
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Recruiting
The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Revival Research Institute - Dearborn, Dearborn, Michigan
Conditions: Type 2 Diabetes